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Allostery is largely associated with conformational and functional transitions in individual proteins.
This concept can be extended to consider the impact of conformational perturbations on cellular
function and disease states. Here, we clarify the concept of allostery and how it controls physiolog-
ical activities. We focus on the challenging questions of how allostery can both cause disease and
contribute to development of new therapeutics. We aim to increase the awareness of the linkage
between disease symptoms on the cellular level and specific aberrant allosteric actions on the
molecular level and to emphasize the potential of allosteric drugs in innovative therapies.Introduction
Allostery is regulation at a distance. It is a universal phenomenon
whereby a perturbation by an effector at one site of the molecule
leads to a functional change at another through alteration of
shape and/or dynamics. Allosteric perturbation is common in
the cell. It arises from noncovalent events, such as binding of
ions, lipids, cAMP, drugs, proteins, RNA, or DNA (Csermely
et al., 2010; Cui and Karplus, 2008; Pan et al., 2010); from light
absorption (Strickland et al., 2008); and from covalent events,
such as phosphorylation, point mutations (Sinha and Nussinov,
2001), or reaction with a small molecule (Figure 1A). Allostery
takes place in all dynamic proteins (Lechtenberg et al., 2012;
Tsai et al., 2008), single chains, and multimolecular assemblies
and in RNA and DNA polymers.
These biomolecules exist in a range of closely related confor-
mational states termed an ensemble. Allostery is a property of
this conformational ensemble, as perturbation at any site in the
structure leads to a shift in the distribution of the conformational
states across the entire population (Fenwick et al., 2011; Kumar
et al., 2000). Thus, allosteric structural and/or dynamic perturba-
tions do not create new conformational states; they only change
the relative distributions of the states within the ensemble.
Interactions at a remote site, like those described above, change
the functional site through the propagation of subtle conforma-
tional changes through physically contiguous and coevolving
amino acids (Reynolds et al., 2011) along pre-existing pathways
(del Sol et al., 2009). Evolution has exploited this purely physico-
chemical phenomenon and has optimized it for function.
Many reviews and research papers have been written on the
allosteric effect; the vast majority of these focus on allostery on
the protein level (e.g., Cui and Karplus, 2008; del Sol et al.,
2009; Endres et al., 2011; Goodey and Benkovic, 2008; Kenakin
and Miller, 2010; Kenakin, 2009; Kuriyan and Eisenberg, 2007;
Leitner, 2008; Ma et al., 2011; Tsai et al., 2009; Tzeng andKalodimos, 2011; Whitley and Lee, 2009; Wrabl et al., 2011;
Zhuravlev and Papoian, 2010; Zocchi, 2009). However, the
fundamental importance of allostery is not in the functional
effects on the protein itself but, rather, on the cell (Good et al.,
2009; Good et al., 2011) and on the organism as a whole.
Cell health and death reflect the functioning of its entire net-
work, and a comprehensive view of the impact of an inactive
or partially active protein can only be achieved by connecting
molecular causes to system outcomes. At its basic level, allo-
stery is indeed a phenomenon related to proteins (or to other bio-
macromolecules, such as DNA or RNA); however, to grasp its full
biological relevance, we need to consider the effects of the
allosteric changes in the protein molecule on its pathway and,
because cellular pathways are interconnected, on the entire
network (Nussinov et al., 2013).
A cell-wide view may lead to questions like: how would the
allosteric change in a single protein propagate to affect other
proteins downstream; and in particular, how would it influence
the behavior of the cell? What would be the impact of a mutation
or of binding of a pathogen protein that disrupts an essential allo-
steric effect? And related to such questions, can we identify the
allosteric cause that leads to the consequent observed disease
syndromes? Addressing such questions that attempt to trace a
global physiological expression to its molecular root is enor-
mously challenging; however, because they encapsulate the
essence of the ‘‘biological allosteric effect,’’ they are of over-
whelming importance, helping to relate symptoms to specific
allosteric effects and effective therapeutics.
Allostery governs regulation and is the means through which
environmental signals are communicated (del Sol et al., 2009;
Kar et al., 2010; Tsai et al., 2009) within, across, and between
cells. This fundamental role of allostery in cellular function under-
scores its relevance to disease. Pathological orthosteric (at the
binding site) and allosteric (elsewhere) events can deregulate aCell 153, April 11, 2013 ª2013 Elsevier Inc. 293
Figure 1. Allostery in Action
(A) Allosteric changes to a biomacromolecule initiate with a localized perturbation such as a binding event, posttranslational modification, mutation (not illus-
trated), or light absorption.
(B) A cellular target of allosteric regulation is schematically represented by three distantly separated sites: the functional site, the allosteric site, and the substrate
site. The cellular perturbation is called orthosteric if it originates exactly at the functional site of a cellular target. On the other hand, if the perturbation is located at a
site that is not in the vicinity of the functional site, it is an allosteric event. As shown, a binding event at the allosteric site initiates a local conformational
disturbance, which creates strain energy that propagates outward, as depicted by the consecutive interactions. It is termed a direct allosteric event if the primary
propagation reaches out to the functional site and directly changes its original state. If the propagation alters the conformational state at the substrate site, which
in turn invokes another event that alters the functional state, it is classified as an indirect allosteric event.
(C) Allosteric cooperativity is illustrated through the catalytic reaction of protein kinase A (PKA, yellow) with three conformations (open, intermediate, and closed)
and four kinase-binding complexes with combinations of cosubstrate ATP (red) and peptide substrate (green). The structures were derived fromPDB entries 1j3h,
1bkx, and 1jlu.
(D) Kinetic framework for substrate binding to PKA. The model invokes experimental kinetic dissociation constants (Kd) for transitions from the apo-kinase (PDB:
1j3h) to the two structures with only the single-substrate bound (PDB: 1bkx and 1jlu) and then to the double-substrate bound kinase (PDB: 1atp). Allosteric
cooperativity is clearly seen in the 3-fold (Kd(1) versus Kd(4)) or 4-fold (Kd(2) versus Kd(3)) improvements in the binding to the second substrate (the transition from
intermediate to closed) as compared to the first substrate affinity (open to intermediate transition). The free-energy landscape in Figure 1C relates themagnitudes
of the binding affinity given in Figure 1D to the relative stability for the four binding states as a function of three conformations (see text for detailed description). PKI
is cAMP-dependent protein kinase peptide inhibitor.protein, trapping it in either an active or inactive conformation.
Uncontrolled protein activity typically leads to disease. When
the protein is trapped in a single state, the signal transmitted is
always switched ON (or OFF), keeping the proteins downstream
in the signaling pathway activated (or inactivated). Because294 Cell 153, April 11, 2013 ª2013 Elsevier Inc.there is crosstalk between pathways, this dysregulation can elicit
multiple disease consequences. From the biological standpoint,
the key problem is whether we can predict the consequences of
a pathological allosteric event to the entire cellular network and
the organism?
We define ‘‘allosteric disease’’ as a disease that can be the
result of a combination of events; however, at least one of these
is the outcome of an allosteric effect. More classically, allosteric
drugs work on the principle that binding of a molecule to a site
remote from the enzyme active site influences the enzyme’s
function. Allosteric diseases and allosteric drugs are rooted in
the same principles and work via the same mechanisms. Allo-
steric drug regimes can integrate allosteric and orthosteric
drugs. However, their successes (and failures) must be assessed
based on the entire system.
In this Review, we first define and explain the basic concept
of allostery in terms of a dynamic free-energy landscape and
in vivo events. From this, we can classify allosteric mechanisms
involved in disease and in allosteric modulator (drug) actions.
We proceed to focus on allostery from the functional standpoint:
how allostery controls cellular function, how it plays a role in
disease, and how it can be harnessed by drugs. Kinases
provide apt examples for detailed mechanistic illustrations to
show how allosteric mutations can cause disease and to
conceptually clarify allostery from a ‘‘systems biology’’ perspec-
tive. Protein kinases are key regulators of cell function and are
one of the largest and most functionally diverse gene families.
They direct the activity, localization, and overall function of a
large number of proteins and orchestrate almost all cellular pro-
cesses (Huse and Kuriyan, 2002; Kim et al., 2006; Taylor et al.,
2005; Taylor and Kornev, 2011). Throughout the Review, we
attempt to cast the pathological and therapeutic allosteric ef-
fects into the framework of the cell, drawing on examples
from the kinase literature. Overall, the Review aims to draw
increased attention to the possible linkage between specific
deleterious allosteric (often gain-of-function) events on the
molecular level and distinct disease syndromes at the cellular
and organism levels. It further highlights the potential impact
of recent advances on allosteric drug discovery. We make the
case that the much-needed new drug classes are likely to
come from allosteric strategies rather than modifications of
existing drug compounds.
The Basic Concept of Allostery
Traditionally, allostery was proposed to operate on the single-
protein level, where binding of an effector molecule at one (allo-
steric) site on the protein surfacewould change the conformation
of another (the active or binding) site and, in this way, regulate
protein activity (Changeux, 2012; Cui and Karplus, 2008; Goodey
and Benkovic, 2008; Tsai et al., 2009) (Figure 1B). Allostery was
formally described in the hemoglobin oligomer as a cooperative
phenomenon with oxygen binding to one monomer enhancing
the affinity of a second oxygenmolecule binding to a neighboring
monomer (Monod et al., 1965).
The paramount advantage of allosteric cooperatively can be
witnessed by the diversity of evolved targets of protein kinases
(Figures 1C and 1D). The phosphorylation reaction occurs as
the free enzyme binds its two substrates, ATP and a polypeptide,
and catalyzes phosphoryl transfer. Activated kinases have been
captured in crystal structures with three distinct conformations
along the reaction coordinates: open, intermediate, and closed.
The open structure refers to the apo-kinase. The intermediate
conformation can reflect kinases with either the ATP cosubstrateor the peptide substrate bound. Binding to both substrates shifts
the protein to the closed structure.
The kinetic scheme for moving from the apo-enzyme to the
fully bound or closed conformation involves four experimental
binding constants (Masterson et al., 2008): Kd(1), Kd(2), Kd(3),
and Kd(4) (Figure 1D). Allosteric cooperativity appears clearly
with a 3- to 4-fold enhancement upon binding of the second sub-
strate (compare Kd(1) to Kd(4)) or (Kd(2) to Kd(3)), reflecting a
conformational transition from an intermediate to a closed state,
as compared to binding of the first substrate (open to intermedi-
ate transition). Figure 1C illustrates the allosteric cooperativity for
the three conformations. The relative stability of each of the four
binding states related to these indicates that it can reflect the
magnitude of the affinity.
Formal descriptions of allostery span energetic coupling
between the two (allosteric and active site) binding events and
the conformational and dynamic changes observed at the active
site following the perturbation by an effector at the allosteric site
(Cui and Karplus, 2008; Fuxreiter, 2012; Hilser et al., 2012; Liu
et al., 2009; Popovych et al., 2006; Tsai et al., 2008; Weinkam
et al., 2012; Wrabl et al., 2011). Formal models of allostery
have also been developed in pharmacology (Maksay, 2011).
All can be clarified by the basic physical fact that bio-
macromolecules consist of ensembles of conformations with a
certain distribution, which can be described by their free-energy
landscape (Figure 2A) (Boehr et al., 2009; Dill and Chan, 1997;
Frauenfelder et al., 1991). An energy landscape is a mapping
of all possible conformations of the protein (or the spatial posi-
tions of the interacting molecules in a system), as a function of
their corresponding energy levels, on a two- or three-dimen-
sional Cartesian coordinate system. This map encompasses
the native conformation as well as any nonnative conformations,
which can be sampled during folding or catalysis. Such a land-
scape description is useful in that it serves as the physical basis
for portraying the ensemble around the native state of the pro-
tein; however, from the biological standpoint, the landscape is
limited, as it provides a static view of the ensemble under a
certain set of conditions, and thus it is unable to explain molec-
ular cooperativity.
To understand how allostery can both render a molecule func-
tional and conversely dysregulate it to cause disease, we have to
consider changes in the free-energy landscape (Gunasekaran
et al., 2004; Ma et al., 1999; Tsai et al., 1999a; Tsai et al.,
1999b). Changes take place because the relative stabilities of
the conformations change following allosteric events (Figure 2B).
For example, allosteric mutations can redistribute the ensemble
to favor the ON state, making the protein constitutively active
(Sinha and Nussinov, 2001). Figure 2 illustrates the principles
of the redistribution of the ensemble when there is an allosteric
mutation (e.g., gain-of-function) or following the binding of
a drug at an allosteric site. As shown, the conformational
ensemble of the regulatory subunit (RA) of protein kinase A
(PKA) undergoes redistribution upon binding to PKA.
Allostery initiates when the protein undergoes some structural
disturbance. This perturbation can be the result of a change in
the physical environment (Figure 1A), including exposure to light
(Strickland et al., 2008); irradiation; change in pH (thus, proton-
ation states; Martı´ et al., 2009); and concentration. It can alsoCell 153, April 11, 2013 ª2013 Elsevier Inc. 295
Figure 2. Linking the Free-Energy Landscape to Allosteric Conformational Switches
The regulatory subunit (RA) of protein kinase A (PKA) exists as an ensemble in two distinct dominant conformations: the B form (either in apo or cAMP-bound) and
the H form (PKA-bound).
(Left) The free energy shifts from the favorable B form in apo-RA (red) to the H form following binding to PKA (green). The accompanying conformational change in
the regulatory subunit due to the binding to PKA (yellow ribbon) is highlighted by two superimposed RAswith the apo B form (PDB: 3iia) in red ribbon and the PKA-
bound H form (PDB: 3fhi) in green.
(Right) The energy landscape shifts from the H form (green) back to the favorable B form (red) after the cAMP (a ball-and-stick model enclosed in transparent
green) preferentially binds the B form of RA (PDB: 3pna) in the red ribbon. The steric hindrance between B form of RA and PKA due to the conformational changes
caused by the allosteric cAMP binding will result in PKA activation by releasing RA.stem from noncovalent binding or a change in a covalent linkage,
such as that taking place during amutational event or when add-
ing or removing a posttranslational modification (PTM) (Nussinov
et al., 2012). To optimize the newly formed interactions, atoms
within the protein move and reorient. This creates strain energy
(or frustration), which forces the next layer of atoms to also
move, which in turn affects the next layer, etc. In this way, the
perturbation travels across the structure through both major
and minor pathways (del Sol et al., 2009) to reach another site
and change its conformation and/or dynamics (Figure 1B).
Thus, allostery works via a ‘‘population shift’’ (Kar et al., 2010);
that is, the distributions of the populations of the conformers in
the ensemble shift, or change, as the allosteric ‘‘wave’’ propa-
gates (Figure 1C, left). The observed cooperativity between the
allosteric and active site is the outcome of such a population
shift. To switch from one conformation to another requires climb-
ing over an energetic barrier. The timescales for the overall
conformational change are determined by the barrier heights
between the different conformations; the higher the barrier, the
slower the change.
The description above emphasizes two key attributes of the
allosteric phenomenon: (1) a static effect, which is reflected by
the final conformational change and (2) a dynamic effect, which
reflects the changes that take place during the propagation of
the allosteric ‘‘wave.’’ Mutations can lead to disease via both
mechanisms. In the first case, mutations may stabilize (or desta-
bilize) the final state, resulting in an ON (or OFF) conformation.
Alternatively, a final change in the structure of the active site
can lead to altered ligand selection. For the second case, allo-
stery acts by changing the relative stabilities along the propaga-
tion pathways in the structure. Such changes can abolish or
create new interatom and intermolecule interactions. Simply
put, the final state, or conformational selection, does not care
about the dynamics leading to it; the dynamic propagation
does not care about the outcome.296 Cell 153, April 11, 2013 ª2013 Elsevier Inc.If the cross-correlation of the motions (e.g., as obtained from
molecular dynamics simulations) between the conformation of
an allosteric site and an active (or functional) site is always ‘‘per-
fect’’ (100%), a mutation that causes a constitutive activation
can be fully described as either stabilizing the active conforma-
tion or disrupting the favorable interactions of an inactive confor-
mation. Nonetheless, the dynamic propagation is important:
even though allostery can be conveniently explained by a popu-
lation shift, propagation clarifies how the change at the allosteric
site modifies a distal active site. A binding event or a mutation
can enhance or restrict allosteric propagation, or it can act via
both propagation and changes in the relative stabilities of the
active versus inactive states. Below, we describe allosteric
disease mechanisms from this standpoint.
How Allostery Controls Physiological Activities
On a single-protein level, the outcome of allosteric propagation
is a highly specific active site conformation. This architectural
specification helps the protein to choose a particular ligand
among the many possible. A slight change in the perturbation
at the allosteric site can lead to different active site conforma-
tions. A regulated protein within a signaling pathway is, in reality,
a population of molecules shaped by allosteric events in which
individual molecules can be differently modified (e.g., phosphor-
ylated) or bound to cofactors or ligands. These events produce
combinatorial effects within the population that define specific
structures and dynamic changes that influence downstream
signaling (Deribe et al., 2010; Nussinov et al., 2012). This
immense complexity is advantageous because it allows the
same protein to bind specifically to different partners, thus ex-
tending functional diversity (Figure 3).
Allostery is not the sole means for conformational selectivity in
the cell. Concentration, availability (Segal and Widom, 2009),
micro-organization (Ferrai et al., 2010; Gavin et al., 2002;Mitchell
and Fraser, 2008; Osborne et al., 2004; Shopland et al., 2003;
Figure 3. Allostery Can Diversify Cellular Signaling Pathways
through a Single Receptor
G-protein-coupled receptors use conformational selection to shape signaling.
Two (different) conformations of GPCR bind two (different) agonists. Binding
stabilizes these two activated conformations, which branch into two path-
ways. In the agonist (G-protein-dependent) pathway, the activated GPCR
either activates the heterotrimeric G proteins, which then promote the
consequent signaling through a second messenger such as cyclic AMP, or
recruits the GPCR kinases (GRKs) to phosphorylate Ser/Thr in the cytoplasmic
loops and tail of the GPCR. In turn, the phosphorylation enables the recruit-
ment of b-arrestins to mediate receptor desensitization and internalization. In
the biased agonist (arrestin-dependent) pathway, distinct active GPCR con-
formations recruit a different set of GRKs. These kinases create distinct
phosphorylation patterns on the GPCR. These patterns impart distinct con-
formations. Via conformational selection, each pattern of modifications re-
cruits a specific conformation of the arrestin (illustrated in different colors)
either through orthosteric or allosteric interactions. Because the resulting
conformation is different, each complex mediates different signaling pathways
such as the ERK 1/2 activation. The illustration is adapted from Figure 5 in
Nussinov et al. (2013), with permission. The illustrated structures are at the
following PDB codes: GPCR, 3ny8 (cyan), 4amj (pink), 3sn6 (light green);
ligands, 3qak (green) and 4amj (red); GRK, 3nyn (blue); arrestins, 3gd1 (orange)
and 3p2d (magenta); G protein, 3sn6 (red, green, and yellow).Sutherland and Bickmore, 2009), recognition domains (Pawson,
2007), etc. are all fundamental parts of the cellular machinery.
However, allostery plays key roles in regulation via molecular
cooperativity and recognition specificity. Because allostery
propagates across molecular interfaces, cooperativity, ligandselection, and specificity affect consecutive components in
cellular pathways.
A prime example of this functional diversification comes from
G-protein-coupled receptor (GPCR) kinases (GRKs) (Figure 3)
(Liggett, 2011). GPCRs exist in an ensemble of conformations.
Different agonists selectively bind distinct GPCR-active confor-
mations and allosterically shift the GPCR population toward
these active states. Distinct GRKs recognize these activated
conformations and phosphorylate them at different serine/threo-
nine residues. The specific arrangements of the phosphorylated
residues on the GPCR serve as blueprints for selective recruit-
ment of specific b-arrestin conformations, which via their allo-
steric scaffolding, stimulate diverse downstream signaling
pathways such as ERK 1/2 activation. Alternatively, distinct
activated GPCR conformations either activate the associated
heterotrimeric G proteins, which then promote the consequent
signaling of a second messenger such as cyclic AMP, or recruit
the GRKs with subsequent selective arrestin binding. Arrestin
binding partially quenches the recruitment of G proteins to
GPCRs, leading to desensitization and internalization.
Allosteric Mutations and Disease
The kinase catalytic core domain contains two lobes connected
by a hinge linker. The active site is located in the deep cleft
between the two lobes, where one cosubstrate, ATP, binds
mostly to the N lobe and the peptide substrate binds to the C
lobe. The catalytic reaction involves a cycle of ATP and pep-
tide/protein substrate binding, phosphate transfer from ATP to
a phosphate receptor residue, and release of ADP and the phos-
phorylated substrate. Kinetic studies have indicated that ADP
release is the rate-determining process of the overall catalytic
reaction (Grant and Adams, 1996), implying that transient
substrate binding and kinase flexibility are important for its func-
tion. As we discuss below, deprivation of flexibility is utilized for
regulation.
The crucial function of an activated kinase requires a popu-
lated conformation that is not only able to bind both ATP and
substrate, but is also able to orient precisely the g-phosphate
of the bound ATP and the hydroxyl group of the phosphate re-
ceptor and to surround them with appropriate catalytic residues
to facilitate the phosphate transfer reaction. Thus, it is not sur-
prising that all activated conformations of the different kinase
families (as captured in crystals) share a strikingly similar struc-
ture (Huse and Kuriyan, 2002; Nolen et al., 2004) in contrast to
the variety of inactivated states awaiting regulation.
The conserved structural elements in the active conformation
are coordinated by the unique hydrophobic and specific electro-
static interactions in order to achieve the precise positioning
required for function. Specific orientation of the key structural
elements, including the aC helix, Gly-rich loop, catalytic loop,
and activation segment (Mg-binding loop, activation loop, and
P+1 loop), are coordinated by the aF-helix via two conserved
hydrophobic interactions—the regulatory spine (R-spine) and
the catalytic spine (C spine) (Taylor and Kornev, 2011) —as
well as some specific electrostatic interactions. Here, we elabo-
rate on the allosteric regulation of the conformational switch
from the inactive aC-helix-out (also referred to as DFG-out)
conformation to the active aC-helix-in (also referred to asCell 153, April 11, 2013 ª2013 Elsevier Inc. 297
Figure 4. Impact of Mutations on Kinase Conformation
(A) Protein kinases are usually held in an inactive state by regulatory interactions. Oncogenic mutations, however, bypass the autoinhibited state and result in
aberrant constitutive kinase activation. There are three general mechanisms for shifting a population from a favored inactive to an active state by mutations via
either stabilizing an active conformation or disrupting critical interactions in an inactive conformation (or a combination of both).
(B) Many kinase families use the allosteric switch from an inactive aC-helix-out to an active aC-helix-in conformation.
(C) Hallmarks of activated kinases (illustrated here for PKA PDB: 1atp) include the presence of a salt-bridge between the b3-lysine and the aC-glutamate (left) and
the formation of regulatory spine (right). The T790M mutation in EGFR (PDB: 3vjn) promotes the assembly of an enzymatically active kinase conformation by
stabilizing the hydrophobic R spine.
(D) Leu858 sits in the middle of a hydrophobic core of inactive EGFR (PDB: 1xkk), suggesting that critical interactions will be disrupted by the L858R mutation,
leading to the shift of the population toward the active conformation. A recent study (Shan et al., 2012b) further indicated that the L858R mutation also stabilizes
the active aC-helix-in conformation from an intrinsically disordered structure through heterodimerization without the help of ligand-induced receptor dimerization.DFG-in) conformation as examples for how allosteric mutations
can cause disease.
As a transducer in signaling pathways, a kinase is usually regu-
lated when in an inactive autoinhibited state, waiting to be stim-
ulated into a partially active and/or fully active conformation via
autophosphorylation. Although there are several mechanisms
of activation, many kinase families use an allosteric switch
from the inactive aC-helix-out state to the active aC-helix-in
conformation through a rotation and shift movement of the aC
helix. The presence of a salt bridge between the b3 lysine and
the aC glutamate (Figure 4C) and the formation of R spine (Taylor298 Cell 153, April 11, 2013 ª2013 Elsevier Inc.and Kornev, 2011) are the two hallmarks of activated aC-helix-in
conformation, distinguishing it from the aC-helix-out state. Prior
to the engagement of the aC-helix patch, the kinase catalytic
core domain is populated mostly in an inactive aC-helix-out
conformation (Jura et al., 2011). Different proteins drive the aC
helix in the activated state through different mechanisms; for
instance, PKA uses its intramolecular C-terminal tail, RET
engages its juxtamembrane segment, the Fes employs an SH2
domain, and EGFR via dimerization. However, oncogenic muta-
tions in the kinase catalytic core domain, which either stabilize
the active aC-helix-in conformation or disrupt interactions
critical for maintaining the inactive aC-helix-out conformation (or
do a combination of both), shift the kinase conformation toward
an active population, resulting in constitutively active aberrant
kinase (Figure 4A). The oncogenic L834R (or L858R in an alterna-
tive numbering of the human EGFR; Figure 4D), accounting for
41% of EGFR mutations in lung cancer patients, belongs to
the latter case. Recent molecular dynamic simulations and
NMR H/D exchange experiments have clarified the mechanism
of this mutation, showing that it works by stabilizing the intrin-
sically disordered active aC-helix-in conformation via heterodi-
merization, even in the absence of a prior ligand-promoted
receptor dimerization (Shan et al., 2012b). On the other hand,
the T790M mutation in EGFR, T315I in BCR-ABL, T334I in
c-ABL, T341I in Src, T670I in KIT, and T674I in PDGFRA promote
the assembly of an enzymatically active kinase conformation by
stabilizing the hydrophobic R spine. These kinase examples
illustrate how allosteric mutations can exploit different mecha-
nisms, even within a single protein family, to reach similar
outcomes, underscoring the importance of in-depth detailed
mechanistic understanding.
Basis for Allosteric Disease Mechanisms
Although many of the disease-causing mutations in proteins that
have been characterized are in binding sites, genetic studies
suggest that, in fact, the majority of these mutations occur else-
where in proteins. Similarly, binding of pathogen proteins (e.g.,
oncogenic proteins E6 and E7 of human papillomavirus (Chi
et al., 2011) and poliovirus (Autret et al., 2007) and apamin, a
neurotoxin in apitoxin [bee venom]), as well as the sun and UV
irradiation, may all interfere with signaling via allosteric mecha-
nisms. As allosteric mechanisms can be traced to some (often
subtle) changes in the relative stabilities of the conformational
states, the consequent disease can take place either (1) because
the final shift in the populations of the ensemble (i.e., the free-
energy landscape) leads to a higher population of ON (as in the
kinases example above) or OFF states or leads to a change in
the active (binding) site shape and dynamics or (2) because of
the dynamic redistribution of the propagation pathways in the
protein structure.
Allosteric mutations can cause disease by either one of the
mechanisms above or by abolishing or creating sites for allo-
steric posttranslational modifications, which can also lead to
similar outcomes. The effects of shifting the relative ON/OFF
populations are described above. Here, we focus on mutations
that can act by shifting major allosteric pathways (Nussinov,
2012; Shan et al., 2012a) or alter patterns of posttranslational
modifications (Deng et al., 2009). Allosteric mutations can un-
couple the distinct conformational changes that normally take
place in an active site upon agonist binding and thus impact
the cellular response. Uncoupling typically occurs bymodulating
a major allosteric propagation pathway between two binding
sites. The mutations can be on or in the microenvironment of
the pathway. For example, disruption of glucocorticoid steroid
signaling plays a role in diverse disease states, including depres-
sion, leukemia, and asthma. Hormones and coregulators bind at
distinct sites in the GR-ligand-binding domain. Mutation of
Met752 to Ile strengthens the GR-peptide interaction while
dramatically slowing hormone association with peptide-boundGR. Themutation disrupts intraprotein communication and com-
promises GR signaling by effectively eliminating hormone bind-
ing as a prerequisite for receptor function (Pfaff and Fletterick,
2010). More generally, a disease may also be caused by muta-
tions located on different pathways or by shifting the ensemble
toward conformations with altered (lower) stability, as in familial
amyotrophic lateral sclerosis (fALS) motor neuron disease (Pfaff
and Fletterick, 2010).
Mutations can deregulate function by affecting posttrans-
lational modifications. Coming back to the kinases, their
extended regulatory spine, which transmits signals from the
regulatory to the catalytic domain, contains conserved residues,
including in the linker between the two lobes. Mutation of
the gatekeeper residue at the edge of the regulatory spine
stabilizes the regulatory spine, resulting in a constitutively active
kinase domain (Figure 4), rendering phosphorylation on the
activation loop unnecessary for its activity (Joseph et al.,
2010). Thus, allosteric disease-causing mutations are common
and can act through diverse mechanisms, depending on the
protein function, conformation, their location in the conforma-
tion, and whether the residue is a target for posttranslational
modification.
Allosteric Diseases versus Allosteric Drugs
Drugs also act via cellular effects. Such networks may vary
across a patient population because of external conditions and
genetics; thus, drug regimes that work for one patient may not
be successful in another even though the symptoms appear
similar.
Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a tumor
suppressor that controls cell fate through transcriptional upregu-
lation of antioxidant response element-bearing genes and
provides an example of allosteric impact with complex network
effects. NRF2 knockout mice under calorie restriction afford
reduced protection from tumorigenesis (Martı´n-Montalvo et al.,
2011). Oxidative stress, or compounds that inhibit the Keap1-
Cul3-Rbx1 E3 ubiquitin ligase, upregulate NRF2 levels and
lead to activation of its downstream target genes. NRF2 activator
drugs such as sulforaphane and tert-butylhydroquinone that
modify Keap1 C151 apparently cause a conformational change
in the Keap1-Cul3 E3 complex, which switches from catalyzing
NRF2 ubiquitination to autoubiquitination of Keap1. Subtoxic
doses of activator drugs, to counter the environmental effects,
are a cancer prevention protocol. At the same time, overex-
pressed NRF2 is responsible for acquired chemoresistance in
tumor cells, which requires suppression of the NRF2 pathway
(Lau et al., 2008). This example highlights the delicate balance
in the cellular network, here relating to cancer prevention versus
cellular resistance.
Mechanisms for Allosteric Drugs
Similar to orthosteric drugs, allosteric drugs can be classified as
either noncovalent or covalent. Low-dosage allosteric drug
regimes using noncovalent binders are likely to be effective if
the protein displays a ‘‘conformational switching’’ mechanism
between the active and inactive conformations. Drug binding
would lead to a shift in the free-energy landscape toward the
inactive conformation. Later, in the absence of the drug, if theCell 153, April 11, 2013 ª2013 Elsevier Inc. 299
energy barriers between the states are high, switching back to
the active conformation may require long timescales, which
may be beneficial in leading to lower drug dosages. Covalent
allosteric drugs are, by contrast, more likely to display irrevers-
ible action even though this reversible/irreversible distinction is
not absolute.
Noncovalent
The vast majority of the currently available allosteric drugs are
noncovalent. Examples include valium and the benzodiazepines,
which target the ionotropic GABA receptor, positive allosteric
modulators of mGluRs (Wood et al., 2011), and positive and
negative modulators of GPCRs (Conn et al., 2009). GPCR
modulators include cinacalcet as a positive regulator at the
Ca2+-sensing receptor and maraviroc as a negative modulator
of the chemokine CCR5 (Smith and Milligan, 2010). In another
example, interdomain communication in the hepatitis C virus
polymerase was abolished by indole-based allosteric inhibitors
binding on the surface of the thumb domain (Di Marco et al.,
2005). We have also described some allosteric drugs, including
anticancer and HIV-1 (Nussinov et al., 2011), and the recently
expanded diversity of the allosteric Bcr-Abl inhibitors provides
additional important examples (Deng et al., 2010). Drugs binding
to RNA can also work via conformational change (Paulsen et al.,
2010).
Covalent Allosteric Drugs
Covalent drugs work in a way similar to that of PTMs: in the
binding site (orthosteric PTMs) or elsewhere (allosteric PTMs;
Nussinov et al., 2012). There are many examples of covalent
orthosteric drugs, including aspirin, although their development
has received mixed reactions because of toxicity concerns
(Singh et al., 2011). Unlike covalent orthosteric drugs, covalent
allosteric drugs are a nascent area. The successful tethering
of allosteric small-molecule inhibitors in the caspases, a class
of cysteine-dependent aspartate-specific proteases, can be
viewed as a first-generation covalent allosteric drug design.
This advance was made possible through the identification of
an allosteric site at the dimer interface of some caspases and
disulfide trapping. Among the trapped thiol-containing frag-
ments, a naphthyl-thiazole-containing molecule selectively
labeled the allosteric cysteine in the p10 subunit of caspase-5
and inhibited it but caused minor inhibition or labeling of
caspase-1. Of interest, some allosteric tethered-compounds to
caspase-5 did not inhibit its enzymatic activity, suggesting that
thiol labeling is not sufficient to drive inhibition and that other
inhibitor-protein interactions also play a role, emphasizing the
challenge in allosteric designs (Gao and Wells, 2012).
Collectively, allostery works similarly in disease and in
response to drugs. Allosteric drugs bind away from the active
site (Figure 1) and, like PTMs, may form a covalent bond with
a reactive residue (Singh et al., 2011). In disease and for allo-
steric modulators, the effects—harmful or beneficial—propa-
gate in the cellular network and may present complex patterns
because of the heterogeneity of the population. Moreover, it is
challenging to predict whether the modulator will enhance
(agonist) or diminish (antagonist) the activity, and even small dif-
ferences, the presence of an additional chemical group, or inter-
action can lead to different—even opposite—modulation effects
(Sadowsky et al., 2011).300 Cell 153, April 11, 2013 ª2013 Elsevier Inc.Advantages and Hurdles Facing Allosteric Drugs
Advantages
Allosteric drugs present several key advantages over orthosteric
drugs that target a protein’s functional site. They are highly spe-
cific because they do not bind in active sites which tend to be
highly conserved in protein families. Their beneficial effect is
compounded in combinatorial strategies, where lower chances
of side effects may be particularly advantageous. They allow
modulation of the protein activity rather than completely elimi-
nating it. Moreover, allosteric drugs generally work when the
endogenous ligand is bound; that is, they work when the cell
needs the protein to work. It is important to note that both small
molecules and biological macromolecules can serve as allo-
steric drugs.
Importantly, allosteric drugs can activate a target protein not
only by directly binding to it, but also by indirect allosteric effects
(Nussinov et al., 2011). For example, whenmultiple receptors are
integrated into one signaling unit, drug binding to one receptor
molecule can allosterically modulate the response of another
to a ligand and thereby create a mechanism of tissue-specific
fine-tuning (Schelshorn et al., 2012). Such indirect allosteric
modulation takes place through protein-protein interfaces (Lee
et al., 2008). This avenue increases the potential repertoire of
allosteric drugs and can further fine-tune modulation.
GPCRs illustrate the concept of indirect allosteric modulation.
Binding of different ligands to distinct GPCR conformations can
activate distinct downstream cascades with the transmembrane
or the extracellular domains communicating the signal across
monomers and higher-order complexes. Allostery in GPCR
heteromers may allow receptor subtype selectivity and tissue
specificity (Smith and Milligan, 2010). For example, in the
glucagon receptor family (GPCR class B), interactions of some
of the receptor combinations decrease upon ligand binding
(Smith and Milligan, 2010). However, an increase in interactions
between receptors was exclusively observed between the
gastric-inhibitory-peptide-receptor (GIPR) and the glucagon-
like-peptide-1-receptor (GLP 1R) upon binding of GLP-1. Addi-
tion of gastric-inhibitory-peptide (GIP) to the GIPR-GLP 1R
heteromer reversed this effect, showing a specific pharma-
cology for GLP-1-induced b-arrestin recruitment and calcium
flux, which suggests allosteric regulation between these func-
tionally related and physiologically coexpressed receptors. GIP
rescued the normal GLP-1 pharmacology and restored GLP-
1R response when expressed alone (Schelshorn et al., 2012).
Allosteric propagation may also be mediated by molecules
other than proteins, which further expands the landscape of
molecular targets. One recent example relates to cholesterol.
Cholesterol has a role in the signaling of endogenous b2-adren-
ergic receptor (b2AR), as it improves b2AR stability and may
mediate receptor-receptor interactions. Remarkably, the crystal
structure of b2AR contains six cholesterol and two palmitic acid
molecules, forming a 2-fold symmetric sheet between the recep-
tors (Cherezov et al., 2007), which raises the question of whether
signaling can be helped by molecules such as cholesterol. This
idea has recently been reinforced by the discovery that oxyster-
ols, which are endogenous signaling molecules, can function in
leukocyte chemotaxis by acting on GPCRs and can also activate
the Hedgehog-signaling pathway by binding allosterically to the
seven-pass transmembrane protein Smoothened (Smo), an
oncology target similar to GPCRs (Nachtergaele et al., 2012). In-
hibition of Smo abrogates the effects of oxysterols on Hedgehog
signaling. This principle of propagation across a signaling unit
may apply across multimolecular complexes as well, where allo-
steric drugs could exploit it (Nussinov et al., 2011). To date, most
allosteric modulators that have been developed target the pro-
tein of interest directly rather than via its neighbors in the func-
tional module, suggesting much room remaining for growth.
The fast growth in the repertoire of allosteric modulators is tes-
tament to their advantages. At the same time, allosteric drugs
posemajor hurdles, some of whichmay be alleviated by effective
allosteric/orthosteric drug combinations.
Hurdles
Allosteric drug discovery is challenging. Unlike orthosteric drugs
that dock into a known active site, allosteric sites are often un-
known and the drug modulatory effects are difficult to predict.
Moreover, slightly different inhibitors or subtly altered inhibitor
interactions may lead to different downstream effects (Sadow-
sky et al., 2011). Allosteric drugs also suffer from the same
hurdles faced by orthosteric drugs—in particular, the emergence
of drug-resistant mutations. These typically lead to alternate
pathways that upregulate activation, as observed for example
in the case of COT-expressing B-RAF(V600E) cell lines, which
exhibit resistance to allosteric MEK inhibitors (Johannessen
et al., 2010). In this case, melanoma cells acquire resistance
to B-RAF(V600E) inhibition by upregulating receptor tyrosine
kinases (RTKs) or N-RAS. Similarly, mutations at positions
Thr315 and Glu255 in Bcr-Abl confer resistance to imatinib
(Adria´n et al., 2006).
Though many allosteric effects can be characterized individu-
ally, drug development targets populations of patients. In this
context, similarity in disease symptoms and in protein levels
does not necessarily imply identical preferred propagation path-
ways because the metabolic and genetic conditions of patients
may vary. In a related vein, network regulation and feedback
loop effects may hinder drug treatments, as in the case of rapa-
mycin and its derivatives temsirolimus and everolimus (rapa-
logs), which are allosteric inhibitors. Rapamycin binds to the
cytosolic protein FKBP12 with subsequent binding of the
complex to the FK-rapamycin-binding domain of mTOR and
selective disruption of mTORC1 assembly. This association
decreases phosphorylation of mTORC1 substrates. However,
while cell survival diminishes, its extent depends on additional
factors such as Akt activation, which relates to its phos-
phorylation on Ser473, the outcome of inhibition of negative
feedback loops. Prolonged rapalog treatment can also decrease
mTORC2-induced Akt activation (Gupta et al., 2012). AsmTOR is
highly regulated by pathways reflecting individual age andmeta-
bolic status, patient diversity is also relevant to the robustness of
the control loops.
Hurdles can also arise from the higher divergence rate of
allosteric sites in species homologs through evolution as
compared to orthosteric sites, which can make translation
from initial pharmacological studies on a heterologously ex-
pressed human receptor family to animal models of disease
even more challenging (Smith and Milligan, 2010). Finally, there
can be toxicity effects. Toxicity often relates to dosage, as highdoses can lead to binding to additional, lower-affinity proteins
or to formation of reactive species by metabolizing enzymes
such as p450; or, they may upset the fine-tuned network
balance. Even though the effective concentration of an allosteric
drug can generally be lower than an active site inhibitor, this
pattern is a trend and not a rule. Specific dosing requirements
may depend on the affinity, as shown by chloroquine, an antima-
larial drug that inhibits the enzymatic activity of the 20S archaeal
proteasome. The low affinity requires high concentrations, which
humans can sustain (Ruschak et al., 2011).
Development of allosteric inhibitors is often pursued for over-
coming clinically acquired resistance mutations to the first
generation of competitive inhibitors, as in the case of ATP-
competitive inhibitors toward Bcr-Abl (Hassan et al., 2010).
Nonetheless, allosteric drugs are not always superior to orthos-
teric drugs, as shown by the rapamycin (mTOR) example above
(Gupta et al., 2012).
Allosteric and Orthosteric Collaboration
One avenue for therapeutic regimes to combat drug-resistant
mutations arising against allosteric drugs is to combine them
with orthosteric drugs. For example, the T315I mutation in the
Bcr-Abl fusion tyrosine kinase is resistant to all ATP-competitive
drugs because it stabilizes the active Abl conformation (Azam
et al., 2008; Medves and Demoulin, 2012; Yun et al., 2007).
GNF-2 is a selective allosteric Bcr-Abl inhibitor. GNF-2 binds
to the hydrophobic myristate-binding site of Abl, mimicking the
myristoyl group. This allosterically leads to changes in the
conformational dynamics of the ATP-binding site and increases
the population of the Bcr-Abl inactive conformation. In com-
bination with ATP-competitive inhibitors imatinib or nilotinib of
Bcr-Abl, GNF-5, an improved analog of GNF-2, showed better
pharmacology: it suppressed the emergence of resistance
mutations and displayed additive inhibitory activity against the
human T315I mutant in vitro the murine bone marrow transplan-
tation model in vivo. Together with these ATP-competitive
inhibitors, GNF-5 was also used to target other imatinib-resistant
Bcr-abl mutants (Adria´n et al., 2006). These results suggest that
combining allosteric and ATP-competitive inhibitors can syner-
gistically help to overcome resistance to either agent alone
(Zhang et al., 2010). However, multiple mutations may arise,
and combination therapies may work only with moderate suc-
cess, as in the case of imatinib/GNF-2. Identification of the alter-
nate cellular pathways and selection of the additional proteins
to target can also be difficult. Complications may also arise
because the alternative pathways may not be identical across
the patient population.
Such drug combinations do not necessarily increase the risk of
toxicity. Examples include allosteric mTOR inhibitors (rapamycin
and RAD001), which were used in combination with dual PI3K/
mTOR kinase inhibitor (PI-103). The combination was more
effective in mutant human ovarian and prostate cancer cells.
The combined inhibition affected Akt phosphorylation and
activation that takes place after treatment with rapamycin. The
combination also inhibited the expression of PI3K/Akt/mTOR
downstream proteins better than either agent alone, leading to
increasing amounts of hypophosphorylated 4EBP1 and selec-
tive inhibition of CAP-dependent translation of c-Myc. NetworkCell 153, April 11, 2013 ª2013 Elsevier Inc. 301
Figure 5. Allosteric Drugs for Kinase Inhibition
The figure provides a few examples of protein kinase complexes with various
allosteric inhibitors.
(A) Orthosteric ATP-competitive inhibitor Gefitinib (red) in complex with active
EGFR kinase (PDB: 3ug2).
(B) Allosteric non-ATP-competitive inhibitor PD318088 (cyan) in complex with
inactive MEK1 kinase and ATP (red) (PDB: 1s9i).
(C) ATP-competitive inhibitor Imatinib in complex with inactive P38 aC-helix-
out conformation (PDB: 3hec).
(D) Allosteric non-ATP-competitive inhibitor bound to C lobe of CHK1 kinase
(PDB: 3jvr).
(E) Allosteric non-ATP-competitive inhibitor bound at the interface between the
PH domain and catalytic core domain of AKT1 (PDB: 3o96).analysis indicated that transcription of all 11 downregulated pro-
teins identified as affected by the combination was regulated by
c-Myc, and the shortest-path algorithm showed that c-Myc
interacts directly with 12 proteins whose abundance was sig-
nificantly reduced by rapamycin. The greater activity of the
drug combination was obtained without an increase in toxicity
as compared to either drug alone (Mazzoletti et al., 2011).
Combinatorial drug regimes are promising. Nonetheless, as
the examples above illustrate, they too may encounter hurdles,
mostly the result of persistent drug resistant mutations. A
database containing multiple combinations encompassing
orthosteric/allosteric drugs targeting the same protein, as well
as combinations targeting parallel pathways may ease the prob-
lem and at the same time help to address patient diversity.Within
such combinatorial framework, the pluses of allosteric drugs can
be expected to make them major players.
Characteristics in Allosteric Regulation
We classify allosteric inhibition based on three useful character-
istics: selectivity (or specificity), potency, and effectiveness.
Binding sites away from the orthosteric active site are usually
considered much more diversified, as they did not sustain direct
evolutionary pressure to preserve key functional residues (Capra
et al., 2009). Therefore, a first characteristic to be specified in
allosteric inhibitor design is the extent of diversification of the
residues involved in binding among the protein family members.
The fact that higher diversity is more tolerant (or less prone) to
network perturbation under high-dose treatment justifies this
condition. A simple genomic survey based on both sequence
and structure alignment should provide the distinct features
that may help to define the selectivity of an allosteric inhibitor.
Second, the potency of an inhibitor depends on the intrinsic
affinity of the inhibitor (the dissociation constant, Ki) and the
competition from the cosubstrate ([ATP] and Km,ATP in the case
of protein kinases; Knight and Shokat, 2005). Though an orthos-
teric inhibitor is by definition competitive with substrate binding
at the active site, allosteric inhibitors are not necessarily sub-
strate competition free. Thus, whether an allosteric drug is sub-
strate competitive or not should be specified to reflect the actual
potency of the inhibition. Because the cosubstrate’s Km displays
large differences with respect to distinct enzyme conformations,
the state of the enzyme to which the inhibitor binds also needs to
be specified. For example, as described above, the protein
kinase core domain is believed to largely populate two states,
an active aC-helix-in conformation and an inactive aC-helix-
Out conformation, with the inactive state being much less
favorable to ATP binding. Figure 5 provides examples of com-
plexes of protein kinases with inhibitors, with the classification
described here.
Conclusions and Perspectives
Proteins function through highly interconnected cellular pathway
linkages; thus, changes in their conformations affect the cell. Yet,
to date, studies of allostery have largely focused on effects in
single proteins and their immediate surroundings. Here, our cen-
tral thesis is that allostery needs to be tackled from a ‘‘systems
biology’’ perspective and that this would help to link aberrant
gain-of-function allosteric events on the single-molecule level302 Cell 153, April 11, 2013 ª2013 Elsevier Inc.to disease syndromes on the cellular (and organism) level.
These insights will foster an understanding of possible effects
of drug regimens and will aid in drug discovery. The example
conceptualized in Figure 3 for G protein signaling clearly argues
for such a view.
Combined with earlier observations, the Review leads to
several major conclusions. (1) In its strictest definition, allostery
takes place in a single protein. But to understand its effects, it
must be put in the framework of the cell (Nussinov et al., 2013).
(2) Allosteric effects propagate across the protein borders to
their partners in complex assemblies (Lee et al., 2008). As a
consequence, combinatorial allosteric effects are likely to be
pronounced in multiprotein complexes, which are shared by
several pathways. This may explain why pathological mutations
in proteins clustered in the same complex, ormodule, can lead to
the same disease. (3) Not all pathological allosteric mutations (or
negative regulatory events, like pathogen protein binding) relate
to long-range allosteric propagation in a protein. Short-range
propagation or shifting of the free-energy landscape by stabiliz-
ing active (or inactive) conformations can also impair native func-
tion. Mutations in the kinases can act in this way. Mutations that
shift the equilibrium toward a dimerization-favored state, as
recently observed by long timescale simulations of the epidermal
growth factor receptor (EGFR), also appear to follow such a
mechanism (Shan et al., 2012b).
The number of possible combinations of allosteric effects is
staggering, making it extremely challenging to predict disease
effects and the outcome of allosteric therapy. Nevertheless, we
believe that the landscape of new classes of drug therapies
will come from allosteric drugs. The diversity of the mechanisms
through which allosteric modulators can act, as illustrated here
through many examples, further emphasizes their potential
heterogeneity. We end on an optimistic note. While drug dis-
covery is challenging and has encountered a meager handful
of successes and many highly costly failures, the allosteric
drug space has barely been explored. The fact that many pro-
teins are considered ‘‘undruggable’’ does not imply that this is
indeed the case. Transient allosteric pockets in these or in pro-
teins with which they interact, directly or indirectly (Nussinov
et al., 2011), can and we expect will lead to therapeutic
advances. Lastly, a combinatorial allosteric drug regime may
show its mettle particularly in combating intractable, tenacious
drug-resistant mutations in which the lower chances of side ef-
fects may allow more extensive collective therapy.
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